PDGFRa (D842V)
Sign in to save this workspacePDGFRA · Variant type: point · HGVS: p.D842V
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Avapritinib | 99.6% | 0.4% | 97.73 |
| 2 | Ponatinib | 98.6% | 1.4% | 78.23 |
| 3 | Nintedanib | 98.3% | 1.7% | 90.23 |
| 4 | Dasatinib | 94.9% | 5.1% | 87.97 |
| 5 | Brigatinib | 94.0% | 6.0% | 82.96 |
| 6 | Erdafitinib | 92.5% | 7.5% | 95.71 |
| 7 | Vandetanib | 91.5% | 8.4% | 95.74 |
| 8 | Pralsetinib | 87.4% | 12.6% | 93.43 |
| 9 | Mitapivat | 87.0% | 13.0% | 100.00 |
| 10 | Sunitinib | 84.4% | 15.6% | 91.73 |
| 11 | Ripretinib | 83.9% | 16.1% | 92.95 |
| 12 | Selpercatinib | 82.6% | 17.4% | 96.72 |
| 13 | Canertinib | 80.5% | 19.4% | 96.49 |
| 14 | Gilteritinib | 79.5% | 20.5% | 88.97 |
| 15 | Pacritinib | 72.5% | 27.5% | 88.64 |
| 16 | Tivozanib | 66.9% | 33.1% | 92.42 |
| 17 | Axitinib | 65.1% | 34.9% | 93.23 |
| 18 | Bosutinib | 64.3% | 35.7% | 87.22 |
| 19 | Fostamatinib | 64.3% | 35.8% | 96.74 |
| 20 | Dacomitinib | 63.6% | 36.4% | 97.99 |
| 21 | Alectinib | 53.3% | 46.7% | 95.49 |
| 22 | Pazopanib | 51.9% | 48.1% | 97.49 |
| 23 | Sorafenib | 49.6% | 50.4% | 96.72 |
| 24 | Imatinib | 46.6% | 53.4% | 99.00 |
| 25 | Osimertinib | 41.7% | 58.3% | 97.24 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Avapritinib | 99.6% | 99.1% | +0.5% |
| Ponatinib | 98.6% | 100.0% | -1.4% |
| Nintedanib | 98.3% | 98.3% | +0.0% |
| Dasatinib | 94.9% | 98.3% | -3.4% |
| Brigatinib | 94.0% | — | — |
| Erdafitinib | 92.5% | 94.5% | -2.1% |
| Vandetanib | 91.5% | 82.0% | +9.6% |
| Pralsetinib | 87.4% | — | — |
| Mitapivat | 87.0% | — | — |
| Sunitinib | 84.4% | 84.2% | +0.2% |
| Ripretinib | 83.9% | 81.5% | +2.3% |
| Selpercatinib | 82.6% | — | — |
| Canertinib | 80.5% | — | — |
| Gilteritinib | 79.5% | 78.1% | +1.4% |
| Pacritinib | 72.5% | — | — |
| Tivozanib | 66.9% | 96.9% | -30.1% |
| Axitinib | 65.1% | 96.0% | -30.9% |
| Bosutinib | 64.3% | — | — |
| Fostamatinib | 64.3% | — | — |
| Dacomitinib | 63.6% | — | — |
| Alectinib | 53.3% | — | — |
| Pazopanib | 51.9% | 74.5% | -22.7% |
| Sorafenib | 49.6% | 95.6% | -46.0% |
| Imatinib | 46.6% | 98.9% | -52.3% |
| Osimertinib | 41.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| gastrointestinal_stromal_tumour_soft_tissue | Soft Tissue | ref |
| carcinoma_large_intestine | Large Intestine | ref |
| other_stomach | Stomach/Digestive Tract | ref |
| other_small_intestine | Small Intestine | ref |
| glioma_central_nervous_system | Brain/CNS | ref |
| gastrointestinal_stromal_tumour_large_intestine | Large Intestine | ref |
| other_large_intestine | Large Intestine | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| other_gastrointestinal_tract_(site_indeterminate) | Soft Tissue | ref |
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| carcinoma_breast | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.8ms